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Despite a wealth of information about the structure and composition of steroid receptors and their functional domains, little is known about the role
of accessory proteins as mediators of receptor activity. To better define the role of such proteins in estrogen receptor (ER) function, we have used
immunoaffinity, steroid affinity, and site-specific DNA-affinity chromatography to identify and characterize proteins that associate with human ER
(hER) in extracts from MCF-7 cells and hER-expressing CHO (CHO-ER) cells. In addition to the expected 66-kDa hER, a 70-kDa protein was obtained
and subsequently identified as a member of the heat shock protein family (hsp70). A 55-kDa protein, detected by all three approaches, was
identified as a member of the protein disulfide isomerase family (PDI). Two proteins that were preferentially retained by an ER-specific DNA affinity
column (p48 and p45) remain unidentified. Maximal interaction of purified hER with the vitellogenin A2 estrogen response element (ERE) occurred
in the presence of all four associated proteins isolated by DNA-affinity chromatography. The increased stability of this complex was due primarily to
an increase in the association rate of hER with ERE. Thus, accessory proteins may be required for optimal interaction of ER with EREs. - Environ
Health Perspect 103(Suppl 7):23-28 (1995)
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Introduction
The cloning and molecular analysis of the
known steroid receptors has led to the
definition of common functional domains
by which they interact with responsive
genes in hormone sensitive tissues (1-4).
As a consequence of these interactions,
DNA synthesis is altered as well as the syn-
thesis of specific RNAs and proteins
involved in cell proliferation, differentia-
tion, and physiologic function and devel-
opment. One member of this family of
transcription factors is the estrogen recep-
tor (ER), which mediates estrogenic
responses in diverse tissues including the
brain, mammary gland, tissues of the
reproductive tract, and cancers derived
from some ofthese tissues (5).
All of the steroid receptors including
ER are activated by one or more ligands
and bind with high affinity and specificity
to short cis-acting DNA sequences called
hormone response elements (HREs).
Interaction of steroid-receptor complexes
with responsive genes in vivo can result in
either induction or suppression of tran-
scription, depending upon the target gene
and the tissue (1,6,7). The molecular
mechanisms by which either pathway
occurs are still obscure although it is gener-
ally accepted that, for transcriptional acti-
vation, receptor-DNA complexes recruit
or facilitate the recruitment of other tran-
scription factors that comprise a functional
transcription complex (3,8). This process
involves protein-protein interactions
between receptor and other factors, which
may be either general [e.g., transcription
factor IIB (TFIIB)] (9), tissue specific (cer-
tain cofactors) (10), or receptor specific
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[e.g., for N-terminal domain of proges-
terone receptor (PR) B isoform] (11).
Some ofthese interactions may result in the
formation of DNA loops (12) to accom-
modate long stretches of DNA between
promoters and HREs or possibly by alter-
ing the local chromatin organization
(13,14) to permit access ofother transcrip-
tion factors. DNA bending may also be
involved (15,16). It has also been suggested
that nonhistone protein acceptor sites
(17,18) that are part of the nuclear matrix
play a key role in receptor action, possibly
by directing receptor to a target gene.
Although such sites have been described,
they have not yet been linked in an obliga-
tory manner to a functional transcription
complex in vivo. Obviously, all or any
combination ofthese processes could occur.
Although it is widely believed that an
allosteric alteration of receptor structure
occurs following hormone binding, which
exposes the DNA-binding domain, the
nature of this change is still not under-
stood. The participation of other proteins,
both before and after hormonal activation,
has been the subject ofmuch investigation
(19). At least three members of the heat
shock protein family have been identified
as putative accessory proteins by virtue of
their association with several receptors in
vitro. One ofthese, hsp90, has been impli-
cated in the in vitro stabilization of the
inactive form of receptors for glucocorti-
coids (GR) (20,21), progestins (PR) (22),
and estrogens (ER) (23). In support ofthe
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hypothesis of an essential role for hsp9O,
recent experiments in which expression of
the hsp9O gene was conditionally regulated
in Saccharomyces cerevisiae demonstrated
that reduced levels of hsp9O severely com-
promised GR transcriptional activity (24).
ER activity was less affected in this model.
In contrast, members of the thyroid (25)
and retinoid (26) receptor family do not
appear to associate with hsp9O, but rather
are synthesized in an active form that is able
to bind to HREs in vivo in the absence of
ligand. hsp56, which was recently identified
as an immunophilin, also appears to be part
of the unactivated complex of several
steroid receptors (27) and may (28) or may
not (29) be able to modify the transcrip-
tional activity ofsome receptors (e.g., PR or
GR) in response to immunosuppressants
such as FK506. It has also been suggested
that p59 (p56) may be the nuclear localiza-
tion signal-binding protein (27). Another
heat shock protein, hsp7O, has been shown
to bind to both PR and GR in the absence
ofhormone but, unlike hsp90, this associa-
tion appears to be maintained, at least in
part, in the activated receptor complex after
hormone treatment (30). A recent study
using baculovirus-overexpressed human GR
in Spodopterafrugiperda cells suggested that
hsp7O is associated with the GR-glucocor-
ticoid response element (GRE) complex
(31). However, Onate et al. (32) observed
that hsp7o was not present or involved in
specific recognition of a progesterone
response element (PRE) by PR. Clearly, the
role ofhsp70 in ER, PR, and GR function
remains unresolved.
An additional class of receptor-associ-
ated proteins are those that interact with
the activated receptor complex. Thus, a 55-
kDa nuclear accessory factor (NAF) has
been reported to be essential for maximal
binding of the vitamin-D receptor (VDR)
to the vitamin-D response element from
the human osteocalcin promoter (33).
Similarly, a 65-kDa factor termed tri-
iodothyronine receptor-auxiliary protein
(TRAP), which exhibits limited indepen-
dent DNA binding, has been shown to
enhance thyroid hormone receptor (TR)
binding to DNA (34). More recently, both
retinoid x receptor a and 3 (RxRa and
RxR,) have been shown to function as
NAF- (35) or as TRAP-like proteins (36)
by forming heterodimers with retinoic acid
receptors (RAR), VDR, and TR. Such het-
eromers can have both positive and nega-
tive transcriptional activity (2). In
addition, one or more members of a het-
eromeric complex may interact with mixed
DNA elements or halfsites in a responsive
gene (37). In regard to other interactions
with activated receptors, the nonhistone
high-mobility-group chromatin protein
(HMG-1) has been shown to substitute for
an unidentified factor present in partially
purified progesterone receptor fractions that
is responsible for promoting PR-DNA
binding (38). Also, an unidentified single
strand DNA-binding protein has been
implicated as being necessary for high
affinity binding of ER to the vitellogenin
A2 estrogen response element (ERE) (39).
In addition, a 110-kDa receptor accessory
factor (RAF) has been observed to potenti-
ate the DNA-binding activity ofthe andro-
gen receptor (AR) in vitro (40). This
protein was recently identified as insulin-
degrading enzyme, and it is not clear what,
ifany, role it plays inARaction.
The nature of agonist-receptor versus
antagonist-receptor interaction and the
resulting altered transcriptional activity are
also still poorly understood at present. It is
very likely that an altered conformation of
receptor occurs in the presence ofan antag-
onist (41), which could affect receptor sta-
bility (42), DNA binding (43,44),
interaction with other transcription factors
such as API (45,46), phosphorylation
(47), or interaction with hsp90 or hsp7o.
It has been proposed for ER that partial
antagonists restrict TAF-2 (transcriptional
activation function) activity but not TAF-I
activity and that the promoter and cell
context is therefore crucial for agonist ver-
sus antagonist activity (48-50). For both
ER (51) and PR (52,53), the pattern of
phosphorylation appears to be essentially
the same in the presence of either agonist
or partial antagonists, suggesting that
altered phosphorylation may not reflect
agonist versus antagonist activity. For
estrogen receptor it has been proposed that
higher order protein-protein interactions
differ when DNA-bound ER is associated
with estradiol versus 4-hydroxytamoxifen
(54). It has also been suggested that some
antagonists, like the "pure" estrogen antag-
onist ICI-164 (or the closely related ICI-
182,780), may interfere with dimerization
(55) or promote receptor degradation
(42). It has recently been observed that the
carboxyterminal tail of at least several
steroid receptors may be a critical determi-
nant of receptor response to ligand and
that antagonism may result from a failure
of antagonists to interact with a 30-amino
acid domain at the carboxy terminus
(56,57). Obviously, there are still a num-
ber of key dynamic and molecular aspects
of ligand-mediated receptor activity that
are not resolved at this time.
Results and Discussion
As discussed above, a wealth ofdata impli-
cates the interaction ofERwith other cyto-
plasmic and nuclear proteins, both before
and after activation by hormone or specific
binding to DNA response elements in tar-
get genes. An objective that has evolved
from our studies on the DNA-binding
properties of the human estrogen receptor
(hER), as well as from the over expression
and purification of hER from mammalian
cells, is the determination of the role of
receptor-associated proteins in DNA bind-
ing, transcriptional activity, or cytoplas-
mic-nuclear transport ofER. In addition to
the association of several heat shock pro-
teins with unactivated receptors described
above, other proteins have been implicated
in the specific recognition of DNA
response elements on target genes by recep-
tors (39) and as mediators of transcrip-
tional activity (9,58). It is also clear that
the TAF-I and TAF-2 functions ofER are
not identical and that their respective roles
in transcriptional activation/repression are
therefore almost certainly mediated by dif-
ferent intermediary factors. These factors
may be cell- and promoter-specific as well
as limiting, as suggested for PR TAF-1
(58), or general, as suggested for TAF-2
(TFIIB)(9). However, it is still unclear
how many different factors participate or
how steroid receptors influence the forma-
tion or stability of transcription initiation
or elongation complexes.
To isolate, identify, and characterize
both cytoplasmic and nuclear ER-associated
accessory proteins, we used immunoaffinity
(H222-Seph), steroid affinity (E-Seph), and
site-specific DNA (B-ERE) affinity chro-
matography to identify proteins that co-
purify with hER in extracts from MCF-7
human breast cancer cells and from CHO
cells stably transfected with hER (CHO-ER
cells) (Figure 1) (59, 60). Analysis ofeluted
proteins by SDS-PAGE revealed similar,
but not identical, patterns ofassociated pro-
teins for each ofthese techniques (Table 1).
In each case, the expected 66-kDa hER was
observed in silver-stained gels as well as on
Western blots. In addition to hER, a 70-
kDa band was retained by all three meth-
ods. Western blot analysis identified this
species as hsp7O. Treatment of CHO-ER
extract in vitro with ATP reduced the
amount ofER-bound hsp70, similar to the
result reported by Smith and Toft for chick
PRtreatedwithATP (19,61).
An additional species that co-purified
with hER by all three methods was a 55-
kDa protein (Table 1) that we have
recently identified by N-terminal amino
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CHO-ER WCE
A B c D
E-Seph +ATP E-Seph B-ERE H222-Seph
E-Seph/ATP Eluate E-Seph Eluate B-ERE Eluate H222-Seph Eluate
(66,55) (70,66,55) (70,66,55,48,45) (70,66,55)
E-Seph
B-ERE/E-Seph EL B-ERE/E-Seph NA
(70,66,55) (48,45)
Figure 1. Purification scheme for hER isolated from
CHO-ER whole cell extract (WCE). (A) Estradiol-
Sepharose chromatography in the presence of ATP (E-
Seph/ATP). (B) Estradiol-Sepharose chromatography
(E-Seph). (C) DNA-Affinity chromatography (B-ERE or B-
ERE'E-Seph). (Note: when a sequential two-step
purification was performed, hER was purified on B-ERE
agarose in the absence of estradiol.) (D) Immunoaffinity
chromatography (H222-Seph). Reproduced with permis-
sion from Landel and Greene (60).
acid sequencing as protein disulfide iso-
merase (PDI) (59,62), or thyroid hormone
binding protein (p55) (63). It is not yet
clear what role PDI may have in ER
action. However, this ubiquitous and
abundant protein is essential for yeast via-
bility (64), and a recent report suggests
that one important function of PDI is to
catalyze disulfide bond formation and
rearrangements within kinetically trapped,
structured folding intermediates (65).
Interestingly, deletion of the catalytic
domain of PDI is not lethal in yeast (66),
suggesting that the essential role ofPDI lies
in a different function. One possibility is
that PDI may serve as a chaperone in the
cytoplasmic/nuclear transport of proteins
since a subpopulation of p55 has been
localized to the nuclear membrane of
humanA431 and rat GH3 cells (67).
Two additional protein bands, which
migrate at 45 and 48 kDa (p45 and p48),
were observed in eluates containing hER
purified on B-ERE-agarose (Table 1).
Although these two bands are also present
to a lesser extent in immunoaffinity eluates,
their intensity is significantly enhanced
when ER is bound to ERE, suggesting that
their association with hER is promoted or
stabilized by ER/ERE interaction. One of
these species may be the 45-kDa single
strand DNA-binding protein identified
earlier by Mukherjee and Chambon (39),
as mentioned above. Although most ofour
studies were carried out with CHO-ER
cells, a virtually identical pattern of ER-
associated proteins was observed by SDS-
PAGE with affinity-purified whole cell
extracts from MCF-7 breast cancer cells.
Because the CHO-ER cells express very
high levels of hER (2-3 x 106 mole-
cules/cell) (68), it is a good model system
for studies ofER-associated proteins.
Table 1. Summary and properties of ER-associated proteins isolated by several chromatographic techniques
(Figure 1).8
Source ofhERb Protein present, kDac Relative DNA binding Rate of association
CHO-ER nuclear extract Total nuclear proteins NA
B-ERE 70,66,55,48,45 ++++
B-ERE- E-Seph EL 70,66,55 ++ ++
B-ERE- E-Seph NA 48,45
E-Seph 70,66,55 ++ ++
E-Seph/ATP 66,55 + +
NA, not available. 'Reproduced with permission from Landel and Greene (60). bThree methods were used to iso-
late hER: site-specific DNA-affinity chromatography (B-ERE); estradiol-Sepharose affinity chromatography (E-
Seph); and estradiol-Sepharose chromatography in the presence of ATP (E-Seph/ATP). A two step purification
using B-ERE followed by E-Seph was also used. The eluate (B-ERE-+ E-Seph EL) and nonadsorbed (B-ERE-+ E-
Seph NA) are indicated above. 'The identity ofthe proteins indicated in the table are: 70, hsp70; 66, hER; 55, PDI;
48 and 45 are unidentified.
To examine possible differential effects
ofestrogen agonists and antagonists in situ
on the interaction ofhER with the associ-
ated proteins listed in Table 1, cells were
metabolically labeled with 35S-methionine
prior to treatment with estradiol (E2), ICI-
182,780 (ICI-182), or 4-hydroxytamoxifen
(OH-Tam). hER was then isolated on B-
ERE-agarose or H222-Sepharose. None of
the tested ligands (E2, ICI-182, OH-Tam)
had any effect on the stoichiometry ofpro-
tein association with hER purified by
adsorption to B-ERE. The same 45-, 48-,
55-, and 66-kDa (hER) bands that were
observed by silver stain were seen in the
autoradiogram except for 35S-hsp70,
which was absent due to the low turnover
rate ofhsp70 (69). However, on Western
blots, hsp70 was readily observed, as were
hER (66 kDa) and PDI (p55). Like the
other three associated proteins (Table 1),
the hsp70/hER stoichiometry was constant
for each in situ treatment.
In contrast to the B-ERE chromatogra-
phy results, when total hER complexes
were isolated by immunoadsorption
(H222-Seph), asignificant reduction in the
amount of associated hsp70 was observed
following treatment of CHO-ER cells in
situ with either estradiol or the partial
antagonist OH-Tam (Table 1), whereas
dissociation ofhsp70 did not occur in the
absence of ligand or when cells were
treated with ICI-182, a complete estrogen
antagonist. In contrast to other published
reports on the effect ofICI-164 (an analog
of ICI-182) on ER stability in mouse
uterus (42), no significant loss of ER was
observed in extracts of CHO-ER cells
treated with ICI-182. The hsp70/ICI-182
results suggest that hsp70 may be required
for high affinity ER/ERE binding and that
a subpopulation of ER that is competent
for DNA binding remains associated with
hsp70. It has been reported that treatment
ofchick PRwith hormone in vitropartially
disrupts its interaction with hsp70 (70).
However, Onate et al. (32) subsequently
observed that hsp70 was not present or
involved in specific recognition ofa proges-
terone response element (PRE) by PR.
Therefore, ER and PR may function differ-
ently with respect to hsp70 interaction. As
mentioned earlier, a recent study suggests
that hsp70 is associated with the GR-GRE
complex (31). Thus, it will be especially
important to determine the role of hsp70
in ER transcriptional activity or in the sta-
bilization ofER/ERE interactions.
Recent data (59) indicate that some or
all of the ER-associated proteins discussed
above can influence the affinity or rate
of ER-DNA complex formation. Two
approaches were used in conjunction with
gel retardation analyses to address this
question: removal ofER-associated compo-
nents and reconstitution experiments.
Purification schemes are outlined in Figure
1. When analyzed by gel retardation (Table
1), maximal binding of hER to the vitel-
logenin 32P-ERE (27 bp of natural vitel-
logenin A2 gene sequence) occurred in the
presence of all four hER-associated pro-
teins (hsp70, p55, p48, p45) that were iso-
lated by B-ERE chromatography (Figure 1,
scheme C). This interaction is at least as
good as the interaction between unpurified
ER (CHO-ER nuclear extract) and the
vitellogenin ERE. Notably, the B-ERE elu-
ate gives rise to two hER/ERE complexes.
Subsequent removal of the p45 and p48
proteins by fractionation ofthe B-ERE elu-
ate on estradiol-Sepharose (E-Seph) in the
presence of 0.7 M NaCl afforded hsp70-
hER-p55 (55,66,70) complex that bound
to 32P-ERE with significantly reduced
affinity (Table 1). The same hsp70-hER-
p55 complex obtained by a single step
purification ofCHO-ER whole cell extract
(WCE) on E-Seph (Figure 1, scheme B),
behaved similarly in gel shift experiments
(Table 1). Proteins in the B-ERE/E-Seph
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nonadsorbed fraction (NA) (Figure 1,
scheme C), which contained only the p45
and p48 species, did not interact with
the 32P-labeled ERE in the absence of
hER, at least under normal gel retardation
conditions (Table 1). However, in the
presence of a large excess of 32P-ERE, a
weak gel-shift complex was observed, sug-
gesting that at least one ofthe two proteins
has some affinity for DNA, similar to the
properties ofthe 45-kDa ER/ERE-binding
protein reported by Mukherjee and
Chambon (39). When CHO-ER WCE
was treated with ATP prior to E-Seph
chromatography (scheme A, Figure 1) to
dissociate hsp70, the estradiol-eluted hER-
p55 (55,66) complex displayed the weak-
est detectable interaction with the 32P-ERE
probe (Table 1), suggesting that hsp7O
mayplay an additional role in stabilizing or
faciliting ER-ERE interaction.
To test whether proteins that were dis-
sociated from hER could be added back to
reconstitute a more active complex, the E-
Seph/ATP eluate (hER-p55, scheme A,
Figure 1) was first treated with an equimo-
lar mixture ofthe p45 and p48 proteins (E-
Seph NA, scheme C; Figure 1). As shown
in Table 1, this combination enhanced the
interaction ofhERwith 32P-ERE. Ifhsp70
was added separately to the ER-p55 com-
plex, a similar enhancement of hER-ERE
interaction was observed, except that in this
case a second, more retarded complex was
also seen, suggesting the formation of an
hsp7O-hER-(p55?) complex. Finally, if all
three proteins (p45, p48, hsp70) were
added to the hER-p55 complex, maximum
hER-ERE formation was observed (Table
1), comparable to the original B-ERE
purified material. In all experiments, a stoi-
chiometric amount of each protein was
added to a known, fixed amount of hER.
Interestingly, a mutant ERE competitor
(GGTCAnnnTGCAC), which has at least
a 10-fold reduced affinity for fully com-
plexed hER (54), competed significantly
for the ER-p55-ERE complex, suggesting
that one or more of the other associated
proteins maycontribute to ER-ERE specifi-
city. Finally, when the rate of ER-DNA
~~- _
E2
Figure 2. Model for hER-associated proteins. Abbreviations: D, DNA binding domain; S. steroid binding domain.
This model is based on our preliminary data and data reported by others for ER, PR, and GR. Contact sites between
hER and p45, p48, and p55 are unknown (indicated by an asterisk). Also, interactions among associated proteins
are not resolved. Reproduced with permission from Landel et al. (59).
binding was assessed by timed gel-shift
experiments, both hsp70 and the combined
p45/p48 proteins contributed separately to
a significant enhancement of the rate of
association (Table 1).
Four conclusions can be drawn from
the above results: a) maximal interaction of
hERwith vitellogenin ERE requires at least
two of the four ER-associated proteins
(45,48,55,70) obtained from the B-ERE
column; b) a subpopulation ofhER that is
competent for DNA binding remains asso-
ciated with hsp70, therefore, hsp7O may be
required for high affinity ER/ERE interac-
tion; c) it is possible to sequentially dissoci-
ate and reconstitute complexes that consist
of hER and at least some associated pro-
teins; and d) reconstitution studies indicate
that a major contribution ofthese ER-asso-
ciated proteins to hER-DNA interaction is
to enhance the rate ofassociation.
Based on our preliminary results, as
well as the published data of others
regarding receptor-associated proteins
(19,27,71), we propose a model (Figure 2)
in which unactivated p55-ER-hsp9O/70
complex loses hsp9O following ligand
binding; the resulting activated ER com-
plex recruits or stabilizes the binding of
two additional proteins (p45 and p48)
when hER binds to ERE. The population
ofliganded hERthat does not bind to ERE
dissociates from hsp7O. Other proteins
(e.g., hsp56, TFIIB) may participate in one
or more of these steps. This model is not
meant to be complete. Future work will
focus on the identification and further
characterization of these and other ER-
associated proteins, especially in regard to
their ability to influence DNA binding or
transcriptional activation by ER. Ofpartic-
ular interest is the mechanisms) by which
some estrogen antagonists (e.g., OH-tam)
appear to be able to promote DNA bind-
ing but then either fail to activate gene
expression or activate only a subset of
genes, possibly by altered interaction ofER
with accessory factors such as those
described above or with other as yet
unidentified intermediary factors.
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